Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG

References

• Modan B. The epidemiology of polycythemia vera. Polycythemia Vera and the Myeloproliferative Disorders, Wasserman, Berk, Berlin 1995; 140–146, Chapter 12. W.B. Saunders Company 1995. Philadelphia USA
   Google Scholar
• Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkezi Jews in northern Israel. Leuk Lymph 1992; 7: 251–255
   PubMed Web of Science ®Google Scholar
• Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992; 48: 20–26
   PubMed Web of Science ®Google Scholar
• Dougan L E, Mathews M LV, Armstrong B K. The effect of diagnostic review on the estimated incidence of lymphatic and hematopoietic neoplasms in Western Australia. Cancer 1981; 48: 866–872
   PubMed Web of Science ®Google Scholar
• Carli P M. Epidemiology of polycythemia vera in Côte d'Or (Burgundy). Nouv Rev Fr Hematol 1994; 36: 147–149
   PubMedGoogle Scholar
• Wasserman L R, Bassen Polycythemia F. J Mount Sinai Hosp 1959; XXVI: 1–49
   Google Scholar
• Wasserman L R. Polycythemia vera, its course and treatment: relation to myeloid metaplasia and leukemia. Bull NY Acad Med 1954; 30: 343–375
   PubMedGoogle Scholar
• Wasserman L R, Berk P D, Berlin N I. Polycythemia vera and the myeloproliferative disorders. W.B. Saunders, Philadelphia 1995, ISBN 0–7216–4213–6
   Google Scholar
• Berlin N I. The diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339–351
   PubMed Web of Science ®Google Scholar
• Ellis J T, Peterson P. The bone marrow in polycythemia vera. Pathol Ann 1979; 14: 383–403
   Google Scholar
• Ellis J T, Peterson P, Geller S A, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hematol 1986; 23: 144–55
   Web of Science ®Google Scholar
• Michiels J J, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group (TVSG). Sem Thromb Hemostas 1997; 23: 339–346
   PubMed Web of Science ®Google Scholar
• Michiels J J, Ewg M PD. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders. Neth J Med 1999; 54: 46–62
   PubMed Web of Science ®Google Scholar
• Kurnick J E, Ward H P, Block M H. Bone marrow sections in the differential diagnosis of polycythemias. Arch Pathol 1972; 94: 489–499
   PubMedGoogle Scholar
• Georgii A, Vykoupil K-F, Buhr Th, Choritz H, Döhler U, Kaloutsi V, Werner M. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 1990; 186: 3–27
   PubMed Web of Science ®Google Scholar
• Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leukemia & Lymphoma 1996; 22(suppl 1)15–29
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka H M, Werden C., Zankovich R, Diehl V, Fischer R. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leukemia Lymphoma 1996; 22: 303–317
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka H M, Diehl V, Fischer R, Michiels J J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leukemia Lymphoma 1999; 33: 207–218
   PubMed Web of Science ®Google Scholar
• Michiels J J. Erythromelalgia and vascular complications in polycythemia vera. Sem Thromb Hemostas 1997; 23: 441–454
   PubMed Web of Science ®Google Scholar
• Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. Clin Lab Haematol 1979; 1: 189–196
   PubMedGoogle Scholar
• Najean Y, Triebel F, Dresch C. Pure erythrocytosis: Reappraisal of a study of 51 cases. Am J Hematol 1981; 10: 129–136
   PubMed Web of Science ®Google Scholar
• Haanen C, Mathe G, Hayat M. Treatment of polycythemia vera by radiophophor or busulphan: a randomized trial. Br J Cancer 1981; 44: 75–80
   PubMed Web of Science ®Google Scholar
• Berk P D, Goldberg J D, Donovan P B, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143
   PubMed Web of Science ®Google Scholar
• Kaplan M E, Mack K, Goldberg J D, et al. Long-term management of polycythiemia vera with hydroxyurea: a progress report. Sem Hematol 1986; 23: 167–171
   PubMed Web of Science ®Google Scholar
• Fruchtman S M, Mack K, Kaplan M E, Peterson P, Berk P D, Wasserman L R. From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Sem Hematol 1997; 34: 17–23
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, de Gaetano G, Marchioli R, Tognoni G, Patrono C, Landolfi R. Gruppo Italiano Studio Policitemia. Polycythemia Vera: the natural history of 1213 patients followed for 20 years. Ann Int Med 1995; 123: 656–664
   PubMed Web of Science ®Google Scholar
• Weitherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet 1978; II: 1219–1222
   Google Scholar
• Messinezy M, Prochazka A, Weitherley-Mein G. Treatment of primary proliferative polycythemia vera by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985; 61: 657–666
   PubMed Web of Science ®Google Scholar
• Katarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Sem Hematol 1997; 34: 24–28
   PubMed Web of Science ®Google Scholar
• Michiels J J, Abels J, Steketee J, van Vliet H HDM, Vuzevski V D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med 1985; 102: 466–471
   PubMed Web of Science ®Google Scholar
• Frezzato M, Ruggeri M, Castamann G, Rodeghiero F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993; 78(II)11–17
   PubMedGoogle Scholar
• Fröhli P, Graf C, Rhyner K. Die Prophylaxe vascularer Komplikationen bei Polycythemia Vera und primarer Thrombozythämie mit niedrig dosierter Acetylsalicylsaure. Schweiz Med Wschr 1983; 113: 1622–1627
   PubMedGoogle Scholar
• Michiels J J, Van Genderen P JJ, Lindemans J, Van Vliet H HDM. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leukemia & Lymphoma 1996; 22(suppl 1)47–56
   PubMed Web of Science ®Google Scholar
• Schefrer M G, Michiels J J, Simoons M L, Roelandt J RTC. Thrombocythemia and coronary artery disease. Amer Heart J 1991; 122: 573–576
   PubMed Web of Science ®Google Scholar
• Michiels J J, Koudstaal P J, Mulder A H, Van Vliet H HDM. Transient neurological and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107–1110
   PubMed Web of Science ®Google Scholar
• Van Genderen P JJ, Lucas I S, van Strik R, Vuzevski V D, Prins F J, van Vliet H HDM, Michiels J J. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemostas 1996; 76: 333–338
   PubMed Web of Science ®Google Scholar
• Van Genderen P JJ, Prins F J, Michiels J J, Schrör K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Brit J Haematol 1999; 104: 438–441
   PubMed Web of Science ®Google Scholar
• Van de Petten J EW, Prochazka V, Singh A, Dickson E R, Wetherley-Mein G. Primary thrombocythemia treated with busulphan. Br J Haematol 1986; 62: 229–237
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain J-D, French P VSG. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–3377
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain J-D, French P VSG. Treatment of Polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997; 89: 2319–2327
   PubMed Web of Science ®Google Scholar
• Silver R T. Interferon-alpha 2b: a new treatment for polycythemia vera. Ann Int Med 1993; 119: 1091–1092
   PubMed Web of Science ®Google Scholar
• Silver R T. A new treatment for polycythemia vera: Recombinant interferon-alpha. Blood 1990; 76: 664–665
   PubMed Web of Science ®Google Scholar
• Silver R T. Interferon-alpha: Effects of long-term treatment for polycythemia vera. Sem Hem 1997; 34: 40–50
   PubMed Web of Science ®Google Scholar
• Taylor P C, Dolan G, Ng J P, et al. Efficacy of recombinant interferon-alpha in polycythemia vera: a study of 17 patients and an analysis of published data. Br. J. Haematol 1996; 92: 55–59
   Web of Science ®Google Scholar
• Elliott M A, Tefferi A. Interferon-alpha in polycythemia vera and essential thrombocythemia. Sem Thromb Hemostas 1997; 23: 463–472
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group. Anagrelide: a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69–76
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein M N, Petitt R M, Meas R A, Solberg L A. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Sem Thromb Hemostas 1997; 23: 379–383
   PubMed Web of Science ®Google Scholar
• Petitt R M, Silverstein M N, Petrone M E. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Sem Hematol 1997; 34: 51–54
   PubMed Web of Science ®Google Scholar
• Solberg L A, Oles K J, Tarah J, Silverstein M N, Petitt R M, Schracter L, Fleming J. The effects of anagrelide on human magakaryopoiesis. Blood 1989; 74(Suppl 1)20, (Abst)
   Google Scholar
• Mazur E M, Rosmain A G, Sohl P A, Newton J L, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 1931–1937
   PubMed Web of Science ®Google Scholar
• Michiels J J. Aspirin and platelet lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Applied Thromb Hemostas 1999; 5: 30–36
   PubMedGoogle Scholar
• Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Sem Thromb Hemostas 1997; 23: 455–461
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythemia vera: a pilot study. Br J Haematol 1997; 97: 453–456
   PubMed Web of Science ®Google Scholar
• Landolfi Marchioli R. R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Sem Thromb Hemostas 1997; 23: 473–488
   PubMed Web of Science ®Google Scholar